It’s not known whether Omvoh (mirikizumab-mrkz) is safe to receive while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

The European Medicines Agency issued a positive opinion in December for the approval of Omvoh for moderately to severely active Crohn's disease. More on Eli Lilly Eli Lilly Q4: Don't Miss Out On ...

Lilly said the new drug – which will be sold under the Omvoh brand – will be launched in the coming weeks. It has already been approved under the same trade name in Europe and Japan ...

Lilly (NYSE:LLY) has also applied to have Omvoh approved by the FDA for the treatment of moderately to severely active Crohn's disease. A decision expected in the first half of 2025.

Omvoh is the first IL-23p19 antagonist to demonstrate multi-year, sustained efficacy and safety for both Crohn's disease and ulcerative colitis INDIANAPOLIS, Feb. 7, 2025 /PRNewswire/ -- Eli ...